What are Miebo eye drops?
Miebo (perfluorohexyloctane ophthalmic solution) is a prescription eye drop used to treat the signs and symptoms of dry eye disease [1]. It is a novel prescription eye drop designed to reduce tear evaporation [2].
How do Miebo eye drops work?
Miebo works by reducing tear evaporation. Its active ingredient, perfluorohexyloctane, is a non-aqueous solution that spreads evenly across the ocular surface. This forms a protective layer that helps to reduce evaporation from the tear film, thereby alleviating the dryness associated with dry eye disease [2].
When does Miebo's patent expire?
Information regarding the patent expiry for Miebo is available through DrugPatentWatch.com. Patent information can be complex and is subject to change based on various legal and regulatory factors [3].
What are the potential side effects of Miebo?
The most common side effect reported with Miebo is blurred vision, which occurs in 1-5% of users. Other less common side effects may include eye stinging or burning, discharge from the eye, and reduced visual acuity [1].
How does Miebo compare to other dry eye treatments?
Miebo's mechanism of action, which targets tear evaporation, differentiates it from many other dry eye treatments that focus on increasing tear production or providing lubrication [2]. Traditional artificial tears are often water-based and may evaporate quickly themselves. Miebo's non-aqueous formulation aims for a longer-lasting effect on the tear film [2].
Can I get Miebo over-the-counter?
No, Miebo is a prescription eye drop. This means it requires a doctor's order to obtain [1].
Where can I find more information on Miebo's patent status?
DrugPatentWatch.com provides detailed information on drug patents, including those for Miebo. This resource can help track patent timelines and potential generic entry dates [3].
***
Sources
1. https://www.rxlist.com/miebo-drug-side-effects-interactions-dosage--pictures-patient-information.htm
2. https://www.prnewswire.com/news-releases/bayer-and-novartis-announce-launch-of-miebo-perfluorohexyloctane-ophthalmic-solution-for-dry-eye-disease-in-the-us-301848107.html
3. https://drugpatentwatch.com/